Similarly, approximately 20% of the compounds predicted to be frequent hitters were also detected by MVS-A. This result is likely because not all frequent hitters would be considered false positives in our benchmark. Our study is set up to measure the ability of an algorithm to detect compounds that elicit a positive readout in the assay without generating the desired biological response. Frequent hitters instead also include compounds that are real assay hits, but are likely to have many off-targets, making further pharmacological development challenging. As such, this definition mismatch likely causes the frequent hitter predictor to perform poorly in this analysis, thus having low correlation with MVS-A scores.